tbuckley/cabot-search huggingface dataset:
206P Disease behavior and treatment response of special histological types of triple-negative breast cancer
Authors: R.R.D.C.C. Bonadio, S.V. Mendes, B.J. Araujo, G. Nader Marta, F.D.A. Costa, P.B.C. Pinto, D. Negrini Batista, L. Testa, M.S.M. Ferrari
Journal: Annals of Oncology (2021)
LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
Authors: K. Fizazi, J. Carles Galceran, S. Foulon, G. Roubaud, R. McDermott, A. Fléchon, B. Tombal, S. Supiot, D.R. Berthold, P. Ronchin, G. Kacso, G. Gravis Mescam, F. Calabro', J.F. Berdah, A. Hasbini, M. Silva, A. Thiery-Vuillemin, I. Latorzeff, I. Rieger, A. Bossi
Journal: Annals of Oncology (2021)
An Outer Membrane Vesicle‐Based Permeation Assay (OMPA) for Assessing Bacterial Bioavailability
Authors: Robert Richter, Mohamed A. M. Kamal, Marcus Koch, Bart‐Jan Niebuur, Anna‐Lena Huber, Adriely Goes, Carsten Volz, Julia Vergalli, Tobias Kraus, Rolf Müller, Nicole Schneider‐Daum, Gregor Fuhrmann, Jean‐Marie Pagès, Claus‐Michael Lehr
Journal: Advanced Healthcare Materials (2021)

When searching for new antibiotics against Gram-negative bacterial infections, a better understanding of the permeability across the cell envelope and tools to discriminate high from low bacterial bioavailability compounds are urgently needed. Inspired by the phospholipid vesicle-based permeation assay (PVPA), which is designed to predict non-facilitated permeation across phospholipid membranes, outer membrane vesicles (OMVs) of Escherichia coli either enriched or deficient of porins are employed to coat filter supports for predicting drug uptake across the complex cell envelope. OMVs and the obtained in vitro model are structurally and functionally characterized using cryo-TEM, SEM, CLSM, SAXS, and light scattering techniques. In vitro permeability, obtained from the membrane model for a set of nine antibiotics, correlates with reported in bacterio accumulation data and allows to discriminate high from low accumulating antibiotics. In contrast, the correlation of the same data set generated by liposome-based comparator membranes is poor. This better correlation of the OMV-derived membranes points to the importance of hydrophilic membrane components, such as lipopolysaccharides and porins, since those features are lacking in liposomal comparator membranes. This approach can offer in the future a high throughput screening tool with high predictive capacity or can help to identify compound- and bacteria-specific passive uptake pathways.
1531P Multi-omic characterization of dedifferentiated liposarcoma: Towards a new model of oncogenesis?
Authors: S. Watson, N. Gruel, J. Vibert, S. Bonvalot, S. El Zein, D. Tzanis, S. Lameiras, E. Girard, M. Galut, M. Lavigne, O. Mariani, S. Baulande, O. Delattre, J. Waterfall
Journal: Annals of Oncology (2021)
A preclinical study of tamoxifen in combination with bevacizumab (Avastin) for the treatment of ER-positive breast cancer
Authors: Anshu Mittal, Yulia Maxuitenko, John Rinehart, William R. Waud, Jaideep Thottassery, Andra R. Frost, William Grizzle, Rongbao Li, Zhican Qu
Journal: Cancer Research (2005)

1091  Clinical studies have shown that elevated levels of VEGF are associated with poor response to tamoxifen treatment for estrogen receptor (ER)-positive breast cancer. Our previous study provided the first direct in vivo evidence that tumor cytosolic VEGF expression at a clinically relevant level not only increases tumor angiogenesis, but also is sufficient to promote ER-positive, tamoxifen-responsive, and non-metastatic breast tumor to become tamoxifen resistant and metastatic. We have developed a xenograft mouse model of ER-positive human breast cancer, in which VEGF expression is tightly controlled by doxycycline in drinking water. The VEGF level detected in the tumor sample is within a range that is found in patient biopsy samples. This study suggested a new function of VEGF in tamoxifen resistance and metastasis and indicated that inhibition of both ER-dependent and VEGF-induced tumor cell growth would be a potential therapy for breast cancer. This study was designed to test this hypothesis using tamoxifen and bevacizumab (Avastin™), a recombinant humanized monoclonal antibody against VEGF. The efficacy of the tamoxifen-Avastin combined therapy was evaluated with two arms of mice designed for early and late stage settings of the disease using the newly developed animal model of ER-positive breast cancer. For the early stage setting, mice received the combined and mono treatments when their tumors reached about 100 mm3 in size. Significant inhibitory effect on primary tumor growth was observed for both the combined treatment and the Avastin mono treatment (P
Trends in Testosterone Prescriptions for Older Men Enrolled in Commercial Insurance and Medicare Advantage
Authors: Alexander Everhart, Katrina Harper, Molly Moore Jeffery, Zachary Levin, Nancy E. Morden, Ashwini Sankar, Pinar Karaca-Mandic
Journal: JAMA Network Open (2021)

This cohort study of health claims data examines trends in testosterone prescriptions for older men in the US following 2014 changes to the US Food and Drug Administration's stance on testosterone's effects and safety risks.
1650P Adoption and early clinical outcomes of atezolizumab (atezo) + carboplatin and etoposide (CE) in patients with extensive-stage small cell lung cancer (ES-SCLC) in the real-world (RW) setting
Authors: D.C.C. Tsui, L. Polito, S. Madhavan, L. Adler, S. Ogale, D.R. Camidge
Journal: Annals of Oncology (2021)
The BMJ Awards 2021: Tackling racist abuse, reducing anaesthetics emissions, and a cartoon inspired talking service take home prizes
Authors: Matthew Limb
Journal: BMJ (2021)

A plan to deal with patients’ racist abuse of hospital staff was among the winners announced at The BMJ Awards 2021 at a virtual ceremony on 29 September.

Other winners included a campaign to reduce carbon dioxide emissions from anaesthetic gases and a talking therapy project inspired by a popular Peanuts cartoon character.

The BMJ Awards showcase innovations and teams who are transforming healthcare.

The BMJ ’s editor in chief, Fiona Godlee, said that the awards had “never been more important” in recognising the professionalism and hard work of staff. “Health professionals continue to face unprecedented pressures, complex challenges, and increased demands as a result of the pandemic,” she said. “But even and perhaps especially in these most difficult of times exceptional projects and people are going above and beyond to improve outcomes for patients. Your commitment and resilience are truly outstanding.”

East London NHS Foundation Trust won the Diversity and Inclusion Team of the Year awards for its action plan to tackle the increasing numbers of racist incidents, which were leading to high staff turnover on an inpatient forensic mental …
513O A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors
Authors: M.L. Johnson, T. Doi, S.A. Piha-Paul, S. Sen, T. Shimizu, B. Cheng, N. Yoshizuka, N. Okamoto, Y. Okuda, X. Qian, G. Serbest, T. Hammett, W.E. Brady, M.R. Patel, J.C. Bendell
Journal: Annals of Oncology (2021)
1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
Authors: J. Bar, W. Kian, M. Wolner, S. Derijcke, N. Girard, Y. Rottenberg, E. Dudnik, G. Metro, M.J. Hochmair, F. Aboubakar, K. Cuppens, L. Decoster, M. Reck, D. Limon, A. Calles Blanco, C. Astaras, S. Häfliger, N. Peled, A. Addeo
Journal: Annals of Oncology (2021)
Abstract 223: S-glutathiolation Uncouples Endothelial Nitric Oxide (NO) Synthase, Switching Enzyme from NO to Superoxide Production
Authors: Chun-An Chen, Lawrence J Druhan, Tse-Yao Wang, Yeong-Renn Chen, Jay L Zweier
Journal: Circulation (2008)

Overproduction of superoxide (•O 2 − ) and •O 2 − -derived oxidants increases cellular oxidative stress. This can lead to cell death, via apoptosis or necrosis. An important response of protein thiols to oxidative stress is reversible formation of protein mixed disulfides via S-glutathiolation. This redox based protein modification is thought to play an important role as an adaptive response to oxidative injury in cells, or alternatively in controlling cellular signaling in a manner similar to phosphorylation. Protein S-glutathiolation is increased in the post-ischemic heart. Human eNOS, which is of critical importance in maintaining cardiovascular function, contains 29 cysteinyl residues. To investigate the effects of S-glutathiolation on the regulation of eNOS function and its relation to cardiovascular diseases, eNOS functional alterations induced by S-glutathiolation were studied. Additionally, LC/MS/MS was used to determine the precise residues of eNOS involved in this redox-dependent thiol modification. S-glutatiolation significantly reduced NO production from heNOS, with a 63% decrease induced by incubation with 2 mM GSSG in vitro . This process was reversible by addition of DTT. Alkylation of the cysteinyl residues with N-ethylmaleimide (NEM) completely inhibited NO production. S-glutathiolation of an uncoupled heNOS increased •O 2 − generation (&gt; 70%), and this increase was only partially blocked by L-NAME, implicating the reductase site as the source for the increased •O 2 − generation. When the cysteinyl residues were all alkylated with NEM, the •O 2 − generation from eNOS was dramatically increased (+2.4-fold), and this increase was not inhibited by L-NAME. We have identified three cysteine residues, C 382 , C 689 and C 908 as sights of S-glutathiolation in heNOS, all three of which are conserved in all known mammalian eNOS enzymes. Therefore, cysteinyl residues are critical for the regulation of eNOS coupling, and S-glutatiolation of specific residues switches eNOS from an NO producing to a •O 2 − generating enzyme, by inducing electron leakage from the reductase domain. As such, S-glutathiolation provides a novel mechanism for the regulation of heNOS, defining a unique pathway for the redox regulation of cardiovascular function. This research has received full or partial funding support from the American Heart Association, AHA Great Rivers Affiliate (Delaware, Kentucky, Ohio, Pennsylvania &amp; West Virginia).
1839P Infectious complications post-cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A meta-analysis
Authors: A. Jain, Z. Mirani, R. Jindal, N.V.D. Kagita, L. Gasparyan, A. Kelaiya, A. Popat, B. Baralo, T. Alukal, P. Kaur, M. Mirani, A. Mulumudi, M. Vyas, A. Kulkarni, D. Patel, V. Sundaram, K. Saed, C.T. Jani, S. Jain
Journal: Annals of Oncology (2021)
18 FDG-PET陽性所見が心電図異常に先行した心サルコイドーシスの一例
Authors: 五十嵐正, 神垣光徳, 木村孔一, 長谷川幸生, 渡邊安寿香, 横田美紀, 池田大輔, 大平洋, 伊東直史, 坂上慎二, 辻野一三, 西村正治, 石丸伸司
Journal: Circulation (2007)
Advancing urban mental health research: from complexity science to actionable targets for intervention
Authors: Junus M van der Wal, Claudia D van Borkulo, Marie K Deserno, Josefien J F Breedvelt, Mike Lees, John C Lokman, Denny Borsboom, Damiaan Denys, Ruth J van Holst, Marten P Smidt, Karien Stronks, Paul J Lucassen, Julia C M van Weert, Peter M A Sloot, Claudi L Bockting, Reinout W Wiers
Journal: The Lancet Psychiatry (2021)
795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158
Authors: D. O'Malley, G.M. Bariani, P.A. Cassier, A. Marabelle, A.R. Hansen, A. De Jesus Acosta, W.H. Miller, T. Safra, A. Italiano, L. Mileshkin, L. Xu, F. Jin, K. Norwood, M. Maio
Journal: Annals of Oncology (2021)
1307P Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1–positive (TPS ≥50%), advanced NSCLC in Japan
Authors: Y. Goto, M.L. Santorelli, K. Taniguchi, T. Kamitani, M. Irisawa, K. Kanda, M. Abe, T. Burke, H. Nokihara
Journal: Annals of Oncology (2021)
Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer
Authors: Yi-Fan Zhou, Yi Xiao, Xi Jin, Gen-Hong Di, Yi-Zhou Jiang, Zhi-Ming Shao
Journal: Journal for ImmunoTherapy of Cancer (2021)

Triple-negative breast cancers (TNBCs), especially those non-immune-inflamed tumors, have a poor prognosis and limited therapies. Human leukocyte antigen (HLA)-I not only contributes to antitumor immune response and the phenotype of the tumor microenvironment, but also is a negative predictor of outcomes after immunotherapy. However, the importance of HLA functional status in TNBCs remains poorly understood. Using the largest original multiomics datasets on TNBCs, we systematically characterized the HLA-Ⅰ status of TNBCs from the perspective of HLA-Ⅰ homogeneity and loss of heterozygosity (LOH). The prognostic significance of HLA-I status was measured. To explain the potential mechanism of prognostic value in HLA-Ⅰ status, the mutational signature, copy number alteration, neoantigen and intratumoral heterogeneity were measured. Furthermore, the correlation between HLA-Ⅰ functional status and the tumor immune microenvironment was analyzed. LOH and homogeneity in HLA-I accounted for 18% and 21% of TNBCs, respectively. HLA-I LOH instead of HLA-I homogeneity was an independent prognostic biomarker in TNBCs. In particular, for patients with non-immune-inflamed tumors, HLA-I LOH indicated a worse prognosis than HLA-I non-LOH. Furthermore, integrated genomic and transcriptomic analysis showed that HLA-I LOH was accompanied by upregulated scores of mutational signature 3 and homologous recombination deficiency scores, which implied the failure of DNA double-strand break repair. Moreover, HLA-I LOH had higher mutation and neoantigen loads and more subclones than HLA-I non-LOH. These results indicated that although HLA-I LOH tumors with failure of DNA double-strand break repair were prone to produce neoantigens, their limited capacity for antigen presentation finally contributed to poor immune selection pressure. Our study illustrates the genomic landscape of HLA-I functional status and stresses the prognostic significance of HLA-I LOH in TNBCs. For "cold" tumors in TNBCs, HLA-I LOH indicated a worse prognosis than HLA-I non-LOH.
Growth Arrest Specific-6 and Axl Coordinate Inflammation and Hypertension
Authors: Justin P. Van Beusecum, Natalia R. Barbaro, Charles D. Smart, David M. Patrick, Roxana Loperena, Shilin Zhao, Nestor de la Visitacion, Mingfang Ao, Liang Xiao, Cyndya A. Shibao, David G. Harrison
Journal: Circulation Research (2021)

[Figure: see text].
1689P Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials
Authors: J. Gulley, M.E. Lacouture, A. Spira, H. Verdaguer Mata, C. Yoo, B.C. Cho, C. Helwig, T. Halady, C. Valencia, M. Bajars, J. Strauss, I. Brownell
Journal: Annals of Oncology (2021)
1485P Identification of novel protein biomarkers for FOLFIRINOX-based chemotherapy response in advanced pancreatic adenocarcinoma using patient omics and Bayesian AI
Authors: A.J. Moser, M. Kiebish, R. Sarangarajan, N.M. Chand, G. Miller, L. Rodrigues, P. Shah, R. Searfoss, K. Ofori-Mensa, V. Tolstikov, B. Greenwood, V. Bussberg, E.M. Grund, C. DeCicco, E. Granger, N.R. Narain
Journal: Annals of Oncology (2021)
1279P The prognostic value of chemotherapy-induced neutropenia (CIN) in patients with advanced non-small cell lung cancer (NSCLC) in the era of chemoimmunotherapy (CIT)
Authors: A. Meisel, M.T. Mark, A. Haider, L. Holer, S. Hayoz, C. Gebhard, S. Bengs, M.J. Hochmair, F. Cappuzzo, M. Reck, R. von Moos, F. Stenner-Liewen
Journal: Annals of Oncology (2021)
290P Treatment with tyrosine kinase inhibitors (TKIs) based therapy in trastuzumab emtansine (T-DM1) resistant HER2-positive metastatic breast cancer: A real-world study
Authors: Y. Hua, C. Sun, M. Jiang, F. Yang, X. Wang, S. Bao, X. Wu, X. Huang, W. Li, Y. Yin
Journal: Annals of Oncology (2021)
954P Comparison of medical costs and outcome between hepatectomy and radiofrequency ablation for hepatocellular carcinoma
Authors: T. Terashima, Y. Higashibeppu, T. Yamashita, Y. Sakata, M. Azuma, K. Fujimoto, H. Munakata, M. Ishii, S. Kaneko
Journal: Annals of Oncology (2021)
Extramedullary disease in multiple myeloma
Authors: Radhika Bansal, Sagar Rakshit, Shaji Kumar
Journal: Blood Cancer Journal (2021)

Abstract When clonal plasma cells grow at anatomic sites distant from the bone marrow or grows contiguous from osseous lesions that break through the cortical bone, it is referred to as extramedullary multiple myeloma (EMD). EMD remains challenging from a therapeutic and biological perspective. The pathogenetic mechanisms are not completely understood and it is generally associated with high-risk cytogenetics which portends poor outcomes. There is a rising incidence of EMD in the era of novel agents, likely a reflection of longer OS, with no standard treatment approach. Patients benefit from aggressive chemotherapy-based approaches, but the OS and prognosis remains poor. RT has been used for palliative care. There is a need for large prospective trials for development of treatment approaches for treatment of EMD.
LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
Authors: J. Cortés, S-B. Kim, W-P. Chung, S-A. Im, Y.H. Park, R. Hegg, M.H. Kim, L-M. Tseng, V. Petry, C-F. Chung, H. Iwata, E. Hamilton, G. Curigliano, B. Xu, C. Lee, Y. Liu, J. Cathcart, E. Bako, S. Verma, S.A. Hurvitz
Journal: Annals of Oncology (2021)
Music production deficits and social bonding: The case of poor-pitch singing
Authors: Peter Q. Pfordresher
Journal: Behavioral and Brain Sciences (2021)

Abstract Both of the companion target articles place considerable performance on music performance ability, with specific attention paid to singing in harmony for the music and social bonding (MSB) hypothesis proposed by Savage and colleagues. In this commentary, I evaluate results from recent research on singing accuracy in light of their implications for the MSB hypothesis.
1774P Exploration of torque teno virus (TTV) levels as marker for immune suppression during systemic therapy in advanced solid cancer patients
Authors: A.M. Starzer, J. Mayer, H. Haselboeck, J. Kreminger, J. Berger, F. Moik, I. Goerzer, M. Preusser, E. Puchhammer, A.S. Berghoff
Journal: Annals of Oncology (2021)
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
Authors: Mazyar Shadman, Marcelo Pasquini, Kwang Woo Ahn, Yue Chen, Cameron J. Turtle, Peiman Hematti, Jonathon B. Cohen, Farhad Khimani, Siddhartha Ganguly, Reid W. Merryman, Jean A. Yared, Frederick L. Locke, Nausheen Ahmed, Pashna N. Munshi, Amer Beitinjaneh, Patrick M. Reagan, Alex F. Herrera, Craig S. Sauter, Mohamed A. Kharfan-Dabaja, Mehdi Hamadani
Journal: Blood (2021)
841P IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas
Authors: K. Li, M.F. Kotturi, M. Manlusoc, R. Yun, P.R. Hinton, K. Logronio, R. Baliga, G. Hernandez, A.M. Sinclair, S.F. Carroll, W.R. Godfrey, B.A. Keyt
Journal: Annals of Oncology (2021)
Abstract 15383: Flavonoid Intake Combats Cardiovascular Disease in Populations With Lifestyle Risk Factors
Authors: Nicola P Bondonno, Frederik Dalgaard, Cecilie Kyrø, Catherine P Bondonno, Joshua R Lewis, Kevin D Croft, Augustin Scalbert, Gunnar Gislason, Kim Overvad, Jonathan M Hodgson
Journal: Circulation (2018)

Introduction: There is increasing evidence that flavonoids, bioactive plant compounds, reduce cardiovascular disease risk. Methods: In 53 126 participants of the Danish Diet, Cancer and Health Stud...
1197P First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN
Authors: Q. Zhou, H.R. Kim, R. Soo, G-C. Chang, C-H. Chiu, H. Hayashi, S-W. Kim, S. Teraoka, Y. Goto, J. Zhou, V.H.F. Lee, B. Han, J.C.M. Ho, D-W. Kim, C-C. Lin, S. Lu, A. Polli, A.M. Calella, T.S.K. Mok, Y-L. Wu
Journal: Annals of Oncology (2021)
Association of Statin Therapy Initiation With Diabetes Progression
Authors: Ishak A. Mansi, Matthieu Chansard, Ildiko Lingvay, Song Zhang, Ethan A. Halm, Carlos A. Alvarez
Journal: JAMA Internal Medicine (2021)

Statin therapy has been associated with increased insulin resistance; however, its clinical implications for diabetes control among patients with diabetes is unknown.To assess diabetes progression after initiation of statin use in patients with diabetes.This was a retrospective matched-cohort study using new-user and active-comparator designs to assess associations between statin initiation and diabetes progression in a national cohort of patients covered by the US Department of Veterans Affairs from fiscal years 2003-2015. Patients included were 30 years or older; had been diagnosed with diabetes during the study period; and were regular users of the Veterans Affairs health system, with records of demographic information, clinical encounters, vital signs, laboratory data, and medication usage.Treatment initiation with statins (statin users) or with H2-blockers or proton pump inhibitors (active comparators).Diabetes progression composite outcome comprised the following: new insulin initiation, increase in the number of glucose-lowering medication classes, incidence of 5 or more measurements of blood glucose of 200 mg/dL or greater, or a new diagnosis of ketoacidosis or uncontrolled diabetes.From the 705 774 eligible patients, we matched 83 022 pairs of statin users and active comparators; the matched cohort had a mean (SD) age of 60.1 (11.6) years; 78 712 (94.9%) were men; 1715 (2.1%) were American Indian/Pacific Islander/Alaska Native, 570 (0.8%) were Asian, 17 890 (21.5%) were Black, and 56 633 (68.2 %) were White individuals. Diabetes progression outcome occurred in 55.9% of statin users vs 48.0% of active comparators (odds ratio, 1.37; 95% CI, 1.35-1.40; P < .001). Each individual component of the composite outcome was significantly higher among statin users. Secondary analysis demonstrated a dose-response relationship with a higher intensity of low-density lipoprotein-cholesterol lowering associated with greater diabetes progression.This retrospective matched-cohort study found that statin use was associated with diabetes progression, including greater likelihood of insulin treatment initiation, significant hyperglycemia, acute glycemic complications, and an increased number of prescriptions for glucose-lowering medication classes. The risk-benefit ratio of statin use in patients with diabetes should take into consideration its metabolic effects.
976P The 30-day mortality rate after first cycle of immunotherapy
Authors: O. Sutcuoglu, A. İlhan, S.Y. Tacar, D.C. Guven, G. Uçar, N. Karadurmuş, F. Yildiz, E. Eraslan, D. Tural, D. Uncu, A. Üner, N. Günel, N. Özdemir, S. Kilickap, Ö.B. Çakmak Öksüzoğlu, A. Özet, O. Yazıcı
Journal: Annals of Oncology (2021)
<i>Notes from the Field:</i> E-Cigarette Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2021
Authors: Eunice Park-Lee, Chunfeng Ren, Michael D. Sawdey, Andrea S. Gentzke, Monica Cornelius, Ahmed Jamal, Karen A. Cullen
Journal: MMWR Morbidity and Mortality Weekly Report (2021)
Robert MacGregor Aitken
Authors: Liz Gill
Journal: BMJ (2021)

A respected retired GP and community stalwart has died at the age of 96. In a medical career spanning over 45 years, Robert MacGregor Aitken (“Roy”) made a huge contribution to his chosen profession not only locally, but also regionally and nationally.

Aitken devoted his working life in Lincolnshire to the advancement of general practice at every level. As well as patient care, he pioneered placement training for junior doctors. This passionate interest led him to serve for five years on the Royal College of General Practitioners’ council for vocational training for general practice in London, of which he became vice chairman, having been an original founder fellow of the college. For this and his other services to medicine he was honoured with an …